Page 3 - Aurora Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aurora science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aurora Science Today - Breaking & Trending Today

Global $3.6 Billion microRNA Markets to 2028 to Grow by 19.8%

Global $3.6 Billion microRNA Markets to 2028 to Grow by 19.8%
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Asia Pacific , Laura Wood , Office Hours Call , Nanostring Technologies Inc , Regents Of The University California , E St Office Hours Call , Merck Kga , Genecopoeia Inc , Horizon Discovery Group Co , Takara Bio Inc , Merck Kgaa , Thermo Fisher Scientific Inc , Trends Analysis Report , Aurora Science , Fisher Scientific , String Technologies , Senior Manager , Free Call , Hours Call , ஒன்றுபட்டது மாநிலங்களில் , ஆசியா பெஸிஃபிக் , லாரா மரம் , அலுவலகம் மணி அழைப்பு , ஆட்சியாளர்கள் ஆஃப் தி பல்கலைக்கழகம் கலிஃபோர்னியா , ஏ ஸ்டம்ப் அலுவலகம் மணி அழைப்பு ,

2021龙岗·大生杯网球俱乐部冠军赛乐城开拍_龙岗新闻网

2021龙岗·大生杯网球俱乐部冠军赛乐城开拍_龙岗新闻网
sznews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sznews.com Daily Mail and Mail on Sunday newspapers.

Longgang Network Association , Health Sports Group Shenzhen , Health Sports Center , Management Center , Sports Council Shenzhen , Longgang News , Shenzhen News , Longgang District , Aurora Science , Technology Limited , ஆரோக்கியம் விளையாட்டு மையம் , மேலாண்மை மையம் , ஷென்சென் செய்தி , அரோரா அறிவியல் , தொழில்நுட்பம் வரையறுக்கப்பட்டவை ,

InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M

InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M
Proceeds to advance clinical evaluation of lead candidate INT-1B3 and further preclinical drug candidates towards the clinic
InteRNA Technologies announced today the closing of an extended Series B financing round amounting to EUR 18.5M in total. This Series B round was led by AurorA Science, an Italian biotech investment company, along with existing investor Waterman Ventures. Current shareholders Aglaia Oncology Funds and OostNL also contributed to the financing round. The funding will enable the clinical evaluation of the Company s microRNA lead candidate, INT-1B3, in patients with advanced solid tumors. Furthermore, the proceeds will be used to develop and advance additional proprietary preclinical drug candidates adressing a variety of cancer indications thereby expanding the Company s pipeline. As part of the Series B financing, Gabriele Campi, PhD, of AurorA Science will join the Board ....

Guido Guidi , Kostenloser Wertpapierhandel , Gabriele Campi , Roel Schaapveld , Trophic Communications , Aurora Science , Aglaia Oncology Funds , Waterman Ventures , Stephanie May , வழிகாட்டி வழிகாட்டி , கேப்ரியல் கேம்பி , அரோரா அறிவியல் , வாட்டர்மேன் முயற்சிகள் , மாற்றாந்தாய் இருக்கலாம் ,

外媒看2021年技术发展趋势：新能源飞机和居家办公技术将快速发展

外媒看2021年技术发展趋势：新能源飞机和居家办公技术将快速发展
jrj.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jrj.com.cn Daily Mail and Mail on Sunday newspapers.

United States , New Market , United Kingdom , San Francisco , Technology News , Usa Service Us , It Service San Francisco , Market Research , Office Service , China Science , Electrical Innovation , Germany France Spain , Rolls Royce Motor Cars , Western Europe , North America , Arizona Phoenix , Independent Service , Aurora Science , Senior Director , ஒன்றுபட்டது மாநிலங்களில் , புதியது சந்தை , மூச்சுத் திணறல் , ஒன்றுபட்டது கிஂக்டம் , சான் பிரான்சிஸ்கோ , தொழில்நுட்பம் செய்தி , சந்தை ஆராய்ச்சி ,

Global Roundup: Russian Vaccine Posts 90% Efficacy, RDIF Says

Published: Dec 17, 2020
By Alex Keown
In August, Russia
approved Sputnik-V, a vaccine against COVID-19 ahead of the completion of Phase III studies. This week, the National Research Center for Epidemiology and Microbiology in that nation announced the vaccine’s efficacy is at 90% following the latest review of clinical data.
The efficacy announcement followed an analysis of Phase III data. Calculation was based on the analysis of data of volunteers who received both the first and second doses of the Sputnik V vaccine or placebo at the third and final control point of 78 confirmed cases in accordance with the Phase III clinical trials protocol, the government said. The advance to the third and final statistically significant representative control point allowed for the final proof of the efficacy of the vaccine of over 90%, the government said. Among the confirmed cases of coronavirus infection, 20 severe cases were recorded in the placebo group, while ....

Baden Wuberg , United States , United Kingdom , British Columbia , Friuli Venezia Giulia , Weil Am Rhein , London Group , Western Australia , Junshi Biosciences , Karolinska Intitutet , Relaxera Pharmazeutische Gmb , Mologic Ltd , National Research Center , Havn Life Sciences , Netherlands Enterprise Agency , Switzerland Sonova Holding , University Of Birmingham , Thermo Fisher , University Of Liverpool , China Overland Pharmaceuticals , London Intuitive Investments Group , University Of Melbourne , Life Sciences , Healthcare Products Regulatory Agency , Thermo Fisher Scientific , Overland Pharmaceuticals ,